文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

临床宏基因组测序在重症监护病房的真实影响:大巴黎地区医院的多中心回顾性研究

Real-life impact of clinical metagenomics in the intensive care unit: a multicenter retrospective study in greater paris area hospitals.
PubMed 文献 · Crit Care · 2026-01-08
一句话结论在ICU真实实践中,mNGS在25.8%患者中检出额外病原体、13.6%为致病性,但仅5.3%病例直接影响治疗,中位周转时间14天可能限制其临床价值。

该多中心回顾性研究纳入大巴黎地区十家三级ICU于2018年1月至2024年4月间临床申请mNGS的132例危重患者(共144次分析),中位年龄55岁,31%免疫功能受损。mNGS在58份样本(40.3%)中检出病原体,胸水检出率(52.4%)高于脑脊液(26.6%)。107株病原体中43株(40.2%)仅由mNGS检出,以胸水和脓肿样本中的厌氧菌为主。mNGS在34例(25.8%)中检出额外病原体,其中18例(13.6%)判定为致病性,7例(5.3%)治疗决策受影响。中位周转时间14天可能限制其临床影响。

要点

  • 在132例ICU患者中,mNGS检出额外病原体34例(25.8%),其中18例(13.6%)判定为致病性。
  • mNGS对胸水样本的病原体检出率(11/21,52.4%)高于脑脊液(16/60,26.6%)。
  • 107株病原体中43株(40.2%)仅由mNGS检出,以胸水和脓肿样本中的厌氧菌为主。
  • mNGS影响治疗决策仅7例(5.3%):5例降阶梯、1例升阶梯、1例临床决策支持。
  • mNGS中位周转时间14天,作者认为这可能限制其临床影响。

适用人群与场景

  • 大巴黎地区十家三级ICU中,临床医生因微生物样本申请mNGS分析的危重患者(共132例,144次分析)。
  • 中位年龄55岁,31%免疫功能受损。
  • 样本类型以脑脊液(60/144,41.7%)和胸水(21/144,14.6%)最常见。

研究设计与关键结果

  • 研究类型:多中心回顾性研究,十家三级ICU,2018年1月至2024年4月,132例患者共144次mNGS分析。
  • mNGS在58份样本(40.3%)中检出病原体;胸水检出率52.4%(11/21)高于脑脊液26.6%(16/60)。
  • 107株病原体中43株(40.2%)仅由mNGS检出,以胸水和脓肿样本中的厌氧菌为主。
  • mNGS在34例(25.8%)中检出额外病原体,其中18例(13.6%)判定为致病性。
  • mNGS影响治疗管理7例(5.3%):5例抗生素降阶梯、1例适当升阶梯、1例临床决策支持。
  • mNGS申请数量逐年增加。

证据类型、等级与局限

  • 证据类型:多中心回顾性研究。
  • 局限:mNGS中位周转时间14天可能限制其临床影响;需进一步研究以更好定义mNGS在危重患者诊断管理中的作用。

对床旁实践的改变

  • 在ICU常规实践中,mNGS可在25.8%患者中检出额外病原体、13.6%判定为致病性,但仅5.3%病例直接影响治疗。
  • 胸水样本mNGS病原体检出率(52.4%)高于脑脊液(26.6%),厌氧菌是仅由mNGS检出的重要病原体类别。
  • 作者认为,中位周转时间14天可能限制mNGS的临床影响,需进一步研究以更好定义其在危重患者诊断管理中的作用。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Infection are the leading cause of intensive care unit (ICU) admission, yet conventional microbiological methods frequently fail to identify the causative pathogen. Metagenomic next-generation sequencing (mNGS) is an emerging, unbiased, pan-pathogen diagnostic tool. However, its real-world microbiological and clinical impact in the ICU remains poorly characterized. This study aimed to assess the microbiological yield and clinical impact of mNGS when implemented in routine ICU practice. METHODS: This retrospective multicenter study was conducted across ten tertiary-care ICUs in the Greater Paris area between January 2018 and April 2024. All patients for whom an mNGS analysis was requested by clinicians from a microbiological sample were included. Any additional pathogens identified by mNGS were independently classified as causative, possibly causative, or non-causative by two reviewers. The independent reviewers also categorised therapeutic changes attributable to mNGS as escalation, de-escalation, discontinuation, or other decision support. Discrepancies were adjudicated by a third reviewer. RESULTS: A total of 144 mNGS analyses were performed in 132 critically ill patients (median age 55 years), 31% of whom were immunocompromised. The number of mNGS analyses requested increased each year. The most common sample types were cerebrospinal fluid (CSF) (n = 60/144, 41.7%) and pleural fluid (n = 21/144, 14.6%). Pathogens were identified by mNGS in 58 samples (40.3%), with a higher yield in pleural fluid (n = 11/21, 52.4%) than in CSF (n = 16/60, 26.6%). Of the 107 pathogens identified, 43 (40.2%) were detected exclusively by mNGS, notably anaerobic bacteria in pleural fluid and abscess samples. mNGS identified an additional pathogen in 34 cases (25.8%) of the 132 patients included, which was deemed causative in 18 cases (13.6%). mNGS findings influenced therapeutic management in seven patients (5.3%) including five cases of antibiotic de-escalation, one appropriate antibiotic escalation, and one case of clinical decision support. CONCLUSION: In this real-life ICU cohort, mNGS identified additional pathogens in 25.8% of patients, deemed causative in 18 cases (13.6%), and a direct therapeutic impact was observed in 5.3% of cases. However, the median turnaround time of 14 days likely limited its clinical impact. Further studies are needed to better define the role of mNGS in the diagnostic management of critically ill patients.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Bay P, Cappy P, Rodriguez C, et al. Real-life impact of clinical metagenomics in the intensive care unit: a multicenter retrospective study in greater paris area hospitals. Crit Care. 2026. PMID: 41508107. doi:10.1186/s13054-025-05764-2

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。